Tech Company Financing Transactions
Braeburn Pharmaceuticals Funding Round
Braeburn Pharmaceuticals, operating out of Princeton, raised $110 million from Wellington Management Company, Apple Tree Partners and Avista.
Transaction Overview
Company Name
Announced On
1/12/2018
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Undisclosed
Investors
Wellington Management Company (Lead Investor)
Avista (Brian Markison)
Proceeds Purpose
Braeburn will use the proceeds to continue to advance the FDA approval process, and commercialize CAM2038, an investigational buprenorphine weekly and monthly depot injection for the treatment of adults with OUD.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47 Hulfish St. 441
Princeton, NJ 08542
USA
Princeton, NJ 08542
USA
Phone
Email Address
Overview
Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. Opioid addiction, also known as opioid use disorder (OUD) is a medical condition requiring medical treatment.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Derkacz
Chief Financial Officer
David McIntyre
Chief Scientific Officer
Sonnie Kim
Vice President
Nancy Leone
VP - General Counsel
Paul Varki
VP - Regulatory Affairs
Ted Buckley
VP - Regulatory Affairs
Susan Franks
Browse more venture capital transactions:
Prev: 1/12/2018: Clevest venture capital transaction
Next: 1/12/2018: Anthera Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs